Aspen Neuroscience has filed to go public on the Nasdaq under the ticker ASPE, potentially becoming the first U.S. public company built around a cell therapy specifically targeting Parkinson's disease. The company's lead program, sasineprocel (ANPD001), is moving into late-stage testing after completing an early-stage trial.
The therapy is personalized: a skin sample is taken from the patient, cells are reprogrammed into induced pluripotent stem cells, then guided into precursor cells that mature into dopamine-producing neurons, and surgically implanted. The entire manufacturing process takes about four months.
Financially, Aspen is burning through cash. It recorded a net loss of $62 million in 2025 and nearly $37 million in the first half of 2026, with research and development making up more than 70% of operating expenses. The company says its current cash won't last another year and that it will need substantial additional capital even after an offering.
The filing comes at a favorable time for biotech IPOs: 24 biotechs have gone public in 2026, a pace not seen since 2021, and 16 raised at least $250 million. Other drugmakers, including Bambusa Therapeutics and Lycia Therapeutics, have also submitted registration documents this month.